Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This study adopts a multicenter, randomized, double-blind, low--high dose groups and placebo
parallel controlled clinical study design. After screening, patients with active ulcerative
colitis who meet the inclusion criteria and do not meet the exclusion criteria will be
randomized by 1:1:1 to Hemay005 45 mg BID group, 60 mg BID group or placebo group, with
proposed 36 patients in each group. All patients will enter a 12-w eek double-blind inductive
treatment period. All randomized subjects who have received the investigational drug should
be subjected to a 4-week observation after the end of treatment.